Theravance Biopharma shareholders are being asked to approve a sale to Zymeworks for USD 17.00 per share in cash plus one non-tradable contingent value right, or CVR. OCC Information Memo 59674, dated August 28, 2026, introduces a different outcome for exchange-listed TBPH options if the merger closes: the anticipated standard contract deliverable is USD 1,700.00 cash, with the CVR excluded.
That difference is the options story. A shareholder package and an adjusted option deliverable do not have to contain the same assets. A trader who values a TBPH call as though each contract will automatically receive 100 CVRs can therefore be using the wrong payoff map.
The transaction has not closed. Theravance’s definitive proxy schedules the shareholder meeting for September 18, 2026, and OCC labels its memo an anticipated adjustment. Final dates and any later contract instructions still depend on the vote, closing, and follow-up OCC notices.
This article is for market commentary and options education only. This is not financial advice. Options trading involves risk and is not suitable for all investors. Review the site’s risk disclosure, the explainer on cash-settled vs. physically-settled options, the guide to options expiration, assignment, and exercise explained, and the primer on early assignment risk.
What OCC memo 59674 says
The proposed merger consideration for each Theravance ordinary share has two parts:
- USD 17.00 in cash.
- One non-tradable CVR tied to possible future value from ampreloxetine.
The definitive proxy describes the CVR as highly speculative. Subject to its detailed terms, it can participate in 80% of certain net proceeds from a license, divestiture, or other monetization of ampreloxetine during a ten-year period. It also describes a possible USD 50 million first-commercial-sale milestone and a 10% net-sales component. None of those payments is assured.
OCC’s anticipated treatment of the listed options is narrower:
| Item | Anticipated term |
|---|---|
| Existing option symbol | TBPH |
| Standard contract deliverable | USD 1,700.00 cash (USD 17.00 x 100) |
| CVR in the adjusted deliverable | Excluded |
| Settlement form | Cash settlement through OCC procedures |
| Current status | Anticipated; subject to merger completion and later OCC instructions |
OCC also alerts call holders that receiving the CVR may require exercise before the adjustment. That is an operational warning, not a recommendation to exercise. Broker deadlines, remaining extrinsic value, settlement timing, capital needs, taxes, and the possibility that the merger does not close all matter.
Why It Matters For Options Traders
The first lesson is that shareholder economics are not automatically option economics. The proxy says ordinary shareholders receive cash plus a CVR at the effective time. OCC, which controls the listed-option adjustment, says the anticipated option deliverable excludes the CVR. The listed contract therefore points to fixed cash while the shareholder package retains a separate contingent right.
The second lesson is that a call can contain a timing choice. A holder who keeps the option through the adjustment is expected to receive exposure to the cash-only deliverable. A holder trying to become a shareholder before the merger effective time would need to consider exercise early enough for the resulting shares to qualify under the final transaction mechanics. That choice can sacrifice remaining time value and can create financing, settlement, tax, and execution consequences.
The third lesson concerns short calls. If some call holders decide that obtaining shares before the adjustment is worth more than preserving the option’s remaining extrinsic value, assignment risk can change. A short-call position should not be treated as insulated merely because the merger price is fixed. The relevant variables are the contract’s time value, the broker’s processing deadlines, and the uncertain value a holder assigns to the CVR.
The fourth lesson is valuation discipline. The CVR is non-tradable and highly contingent. Even a shareholder cannot treat it like certain cash, and an exchange-listed call does not receive it under OCC’s anticipated deliverable. A quote that looks cheap or expensive against USD 17.00 plus some guessed CVR value may simply be reflecting the actual cash-only option terms.
The important distinction between company awards and listed options
Theravance’s merger filings discuss treatment of company-issued employee equity awards. Certain in-the-money company options are slated to receive a cash amount based on the USD 17.00 consideration plus CVRs tied to their underlying shares.
Those company awards are not the same instrument as exchange-listed TBPH options. The merger agreement governs the employee awards; OCC memo 59674 governs the anticipated adjustment of listed contracts. Mixing the two rulebooks is an easy way to reach the wrong conclusion.
How to read the setup before the vote
Bullish interpretation
The cash component provides a stated merger value of USD 17.00 per share, and the CVR preserves a possible additional payment for qualifying shareholders if ampreloxetine later produces specified proceeds or sales. For calls, however, that contingent upside matters only through pre-adjustment share ownership and the market’s behavior before closing; it is not part of OCC’s anticipated cash deliverable.
Bearish interpretation
The merger still requires shareholder approval and other closing conditions. The CVR may never pay anything, and exercising a call to pursue it can exchange a liquid option for shares exposed to deal failure and closing timing. An option holder can also give up extrinsic value or incur financing costs by exercising early.
Neutral and risk-management interpretation
The cleanest reading is contractual. Before taking action, identify whether the position is a listed option or a company equity award, verify the exact deliverable, check the option’s remaining time value, and ask the broker how exercise and settlement deadlines would be handled. Then monitor later OCC notices instead of treating memo 59674 as a final closing notice.
Common misunderstandings and caveats
“Every TBPH call will receive 100 CVRs”
No. OCC’s anticipated standard option deliverable is USD 1,700.00 cash and excludes the CVR. The shareholder merger consideration is a separate package.
“Exercising guarantees the CVR”
No. OCC says call holders seeking the CVR may need to exercise before the adjustment, but eligibility depends on the final closing timeline, share settlement, transaction terms, and broker processing. Exercise also gives up any remaining option time value.
“The CVR is just extra cash above USD 17”
No. Theravance’s definitive proxy calls the CVR payments highly speculative and says there is no assurance any qualifying transaction or payment will occur. The right is non-tradable and its value cannot be assumed from the headline terms.
“The OCC memo means the merger is complete”
No. Memo 59674 is an anticipated cash-settlement notice. The shareholder meeting is scheduled for September 18, 2026. The merger, adjustment date, and final expiration handling remain subject to subsequent events and notices.
“Cash settlement removes assignment and exercise risk”
No. The anticipated end-state is cash-only, but exercise decisions can occur before the adjustment and short calls can still be assigned. Cash settlement changes the deliverable; it does not erase the operational path to get there.
What to monitor next
- The September 18 shareholder vote and any adjournment.
- A company announcement confirming whether and when the merger closes.
- A final OCC memo confirming the effective adjustment date, cash settlement, and expiration treatment.
- Broker-specific deadlines for voluntary exercise and any restrictions on adjusted contracts.
- Remaining extrinsic value and quoted liquidity as the vote and possible closing approach.
Bottom line
OCC memo 59674 exposes a subtle but important split. Theravance shareholders would receive USD 17.00 cash plus one non-tradable CVR if the Zymeworks merger closes, while the anticipated deliverable for a standard listed TBPH option is USD 1,700.00 cash only. The CVR is excluded.
For options traders, the useful response is not to guess a value for the CVR and add it to every call. It is to verify which instrument is owned, understand the cash-only listed-option deliverable, measure the cost and risk of any exercise decision, and wait for final OCC instructions. This is not financial advice.
Sources
- OCC Information Memo 59674, “Theravance Biopharma, Inc. - Anticipated Cash Settlement” (plain-text URL):
https://infomemo.theocc.com/infomemos?number=59674 - Theravance Biopharma definitive merger proxy, filed August 21, 2026 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/1583107/000110465926099364/tm2621435-2_defm14a.htm - Theravance Biopharma Form 8-K and merger agreement summary, filed June 29, 2026 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/1583107/000110465926078453/tm2619064d1_8k.htm - Theravance Biopharma merger announcement, June 29, 2026 (plain-text URL):
https://www.sec.gov/Archives/edgar/data/1583107/000110465926078454/tm2619064d2_ex99-1.htm
